Skip to content

Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal

Combined Strategy of Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal in Patients With Acute Kidney Injury

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02595619
Enrollment
14
Registered
2015-11-03
Start date
2015-12-31
Completion date
2017-03-31
Last updated
2017-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

AKI, Extracorporeal Carbon Dioxide Removal, Renal Replacement Therapy, Mechanical Ventilation

Brief summary

This study aims to assess whether in patients with acute kidney injury (AKI) requiring mechanical ventilation, a strategy that combines renal replacement therapy (RRT) and extracorporeal carbon dioxide removal (ECCO2R) allows reduction of tidal volume and plateau pressure. Systemic Inflammatory Response and Safety Variables will also be analysed.

Interventions

DEVICERRT plus ECCO2R

Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment

Sponsors

University of Turin, Italy
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients with acute kidney injury (AKI) requiring renal-replacement therapy and mechanical ventilation of duration ≥ 48 hours

Exclusion criteria

* little chance of survival at 24 h (according to clinical judgment), pregnancy, mechanical ventilation with expected duration lower than 48h, age under 18 and over 90

Design outcomes

Primary

MeasureTime frame
Achievement of tidal volume reduction to 4 mL/kg while maintaining pH and PaCO2 to ± 20% of baseline values72 hours

Secondary

MeasureTime frameDescription
Evaluation of inflammatory mediators release in plasma samples of patients72 hoursPlasma Concentrations of interleukin 6, interleukin 8, interleukin 1 beta, tumor necrosis factor alpha
Assessment of the changes in pH72 hours
Assessment of the changes in PaCO272 hours
Assessment of the changes in PaO272 hours

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026